For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said Maria ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

How to Get Compounded Tirzepatide To get compounded tirzepatide, you’ll go through all of the same steps listed above.

Findings at week 176 demonstrated that among prediabetic patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free. Detailed results were ...

Taylor Hill/WireImage Bunnie Xo is sharing an update on how she’s feeling on tirzepatide, joking she’s “never gonna be a sex symbol” because she only makes headlines for “how I wear diap ...

As reported in August, the highest dose of tirzepatide tested—15 mg—also helped patients lose an average of 22.9% of their body weight, versus just 2.1% in the trial’s control arm. Patients ...

In a phase-3 randomized controlled trial published in the New England Journal of Medicine, researchers investigated the effects of tirzepatide on weight reduction and diabetes prevention in ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products that claimed to contain tirzepatide, the main ingredient in its popular weight-loss medicine ...

When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction.

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and obese or overweight people over 176 weeks; shares rose modestly after ...